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Erythropoietin (EPO) is an essential growth factor that regulates erythrocyte production in mammals. In this study, we demonstrate a
novel role of EPO in regulating angiogenesis in vivo. Epo and Epo receptor (EpoR) are expressed in the vasculature during embryogenesis.
Deletion of Epo or EpoR leads to angiogenic defects starting at E10.5, 2 days before ventricular hypoplasia and 3 days before the onset of the
embryonic lethal phenotype. Overall, angiogenesis was severely affected in the mutant embryos: vascular anomalies included decreased
complexity of the vessel networks. However, de novo vasculogenesis remained intact, consistent with the differential expression of Epo and
EpoR during the early stages of embryonic development. The aforementioned angiogenesis defect can be partially rescued by expressing
human EPO during embryogenesis. Moreover, Ang-1 expression is regulated by EPO/EPOR under normoxic conditions. Taken together, our
results suggest important roles of EPO and EPOR in angiogenesis.
D 2004 Elsevier Inc. All rights reserved.
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Erythropoietin is a principal hematopoietic growth factor
responsible for the proliferation, survival, and differentiation
of erythroid progenitor cells. Through specific binding to its
cognate receptor, EPOR (D’Andrea et al., 1989a,b), EPO
triggers a chain of intracellular signaling events, including
activation of the receptor-associated tyrosine kinase JAK2
and phosphorylation and nuclear translocation of STAT5,
leading to progenitor cell proliferation and differentiation
(Watowich et al., 1996). In addition to erythropoiesis, EPO
has been found to be important for megakaryocyte
proliferation and differentiation.
Recent studies suggest that the functions of EPO and
EPOR are not strictly limited to erythroid or hematopoietic
lineages. For instance, EpoR expression has been detected
in umbilical cord and placental endothelial cell lines, and
EPO was capable of stimulating endothelial cell prolifer-0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: hwu@mednet.ucla.edu (H. Wu).ation in vitro (Anagnostou et al., 1990, 1994). In addition,
EPO was known to induce a pro-angiogenic phenotype in
cultured endothelial cells and stimulated neo-vascularization
in the chick chorioallantoic membrane (Ribatti et al., 1999).
EPO plays an important role in cardiac morphogenesis (Wu
et al., 1999), in myoblast proliferation (Ogilvie et al., 2000),
and possibly in neurogenesis (Yu et al., 2002). Despite these
advances, a detailed analysis of Epo and EpoR expression
patterns and their in vivo functions in these non-erythroid
lineages are currently lacking.
To understand the possible roles of EPO in these
nonhematopoietic lineages and during embryogenesis, we
have performed a detailed in situ hybridization analysis
comparing the expression profiles of Epo and EpoR from
6.5 to 11.5 dpc. High levels of Epo and EpoR expression
can be detected in the vasculature and the heart. Consistent
with their expression patterns, we found that Epo and EpoR
null embryos are defective in angiogenesis while relatively
normal in vasculogenesis. Thus, our results provide the first
in vivo evidence for the functions of EPO and EPOR in vivo
in angiogenesis.276 (2004) 101–110
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Animal breeding and embryo harvesting
Mice with deletions in the Epo or EpoR genes have been
described (Wu et al., 1995, 1999). The morning when the
vaginal plug could be detected was defined as embryonic
day 0.5 (E0.5). Somite and presomite embryos were staged
according to criteria previously described (Downs and
Davies, 1993).
In situ hybridization
Embryos were fixed overnight in 4% paraformaldehyde
(in PBS) at 48C. Nonradioactive whole-mount mRNA in
situ hybridization technique was performed as previously
described (Belo et al., 1997). Digoxigenin-labeled ribo-
probes were synthesized from a BamH1/EcoR1 500-bp
fragment of murine Epo cDNA corresponding to exons 4
and 5, and a XhoI/HindIII 949-bp fragment corresponding
to 270–1219 of the EpoR cDNA (Lee et al., 2001).
Embryos, post in situ hybridization, were embedded in
liquid paraplast and sectioned at 7 Am. The sections were
photographed.
Histology and immunohistochemistry
Whole-mount immunohistochemistry for visualization of
vasculature was performed according to protocol described
by Koblizek et al. (1998) using an antibody specific to
mouse PECAM (anti-CD31, Pharmingen). HRP-conjugated
secondary Antibody (Roche) was used followed by DAB
staining.
Northern blot analysis
RNA was isolated with Qiagen RNA miniprep kit
according to the manufacturer’s protocol. Total RNA were
separated by a 1% agarose gel and transferred onto a nylon
membrane. The RNA was immobilized on the membrane
by UV cross-linking and dried at 808C for 2 h. The blot
was prehybridized at 658C in QuickHyb hybridization
solution (Stratagene) for 30 min and then hybridized for 1
h with VEGF and Ang-1 cDNA probes labeled with
[a-32P] dCTP by using a random primer labeling kit
(Stratagene). The blot was washed as recommended by
Stratagene. Hybridization signals were visualized by
radiography and quantified using Scion Image software
(NIH, Bethesda, MD), using a Kodak gray color scale as a
standard. Each membrane was stripped and reprobed with
labeled actin probe for loading control.
HUVEC cell culture
Normal HUVEC were obtained from Cambrex (Bio-
Whittaker) and maintained in EBM2 medium supplementedwith 0.1 mg/ml endothelial cell growth supplement (crude
extract from bovine brain), penicillin (50 U/ml), streptomy-
cin (50 U/ml), 2 mmol/l glutamine, and 0.1 mg/ml sodium
heparin. Aliquots of cells were preserved frozen between
passages 1 and 3. For all experiments, HUVECs were used
at passages 4 or below and collected from a confluent dish.
Cells were treated with 10 Units of rHEPO (a gift from
Amgen) and cells were collected at 2 and 5 h after
stimulation.
Epo transgenic mice
The full-length human Epo cDNA (HindIII–ApaI) was
cloned into the HpaI site of the plasmid bMHC, which
contains the beta myosin heavy chain promoter and 5V
untranslated sequence of the hEpo start and termination
codons, as well as a human growth hormone 3VUT and poly
A sequence (Rindt et al., 1993). Transgenic mice were made
by pronuclear injection and founder mice were identified by
PCR analysis using primers of 5V-ACTCCTGAGTGCT-
GAGCA-3Vand 5V-CCTAGTCAAACAAAATGATGCA-3V,
which amplifies a fragment of 800 bp. Five founders
survived to adulthood but three died 4–7 weeks after birth
due to, at least in part, spleenomegaly and extremely high
hematocrit (97%). Two surviving lines, with hematocrit
ranging 60–75%, were used for further studies.
FITC-lectin injection
Half milliliter of FITC-Lectin (Vector Laboratories, 40
Ag/ml in PBS) was injected into each mouse via tail vein
under anesthesia (40 Al/mouse of ketamine 100 mg/ml and
xylazine 20 mg/ml mixed 4:1 solution). One minute later,
the mice were perfused with 1% paraformaldehyde (in PBS)
for 2 min and then perfused with PBS for 2 min by cardiac
perfusion. Then, the peritoneal membranes were dissected
out, mounted on slide, and observed under fluorescent
microscope.
Real-time quantitative PCR
Assays were performed using an Applied Biosystems
7700 sequence detector. Briefly, 1 Ag of total RNA was
reverse transcribed with random hexamers using the
Taqman reverse transcription reagent kit (Applied Bio-
systems) according to the manufacturer’s protocol. Each
Taqman reaction (50 Al) contained 50 ng of cDNA, 900
nM forward primer, 900 nM reverse primer, 100 nM dual-
labeled fluorogenic probe (IDT), and 25 Al of Universal
PCR Master mix (Qiagen). PCR thermocycling parameters
were 958C for 10 min, 40 cycles of 958C for 15 s, and
608C for 1 min. All samples were analyzed for 36B4
expression in parallel. The quantitative expression values
were extrapolated from standard curves for VEGF or
36B4. Each sample was run in duplicate and was
normalized to 36B4. The replicates were then averaged
and fold induction was determined. Statistical analysis of
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tailed, homoscedastic t test. Probe and primer sequences
are available upon request.Results
Differential expression of Epo and EpoR during early
vasculogenesis
The vascular system develops earlier during embryo-
genesis, both extraembryonically and intraembryonically, to
satisfy the metabolic requirements for gastrulation and
organogenesis. To study the possible roles of EPO and
EPOR in early vasculogenesis, we performed detailed in situ
hybridization analysis on E6.5–E9.0 embryos to investigate
the timing and location of Epo and EpoR expression.
Whole-mount in situ hybridization analysis revealed that
EpoR expression starts as early as E7.5 in the extraem-
bryonic coelemic cavity and mesoderm derived allantois
(all, arrows) (Figs. 1a,d). This expression pattern continues
until late neural fold stage, at which time EpoR expression is
clearly evident in the yolk sac blood islands (bi) (Fig. 1b).
During early embryogenesis, vasculogenesis in the yolk sacFig. 1. Whole-mount in situ hybridization analysis of EpoR and Epo expressions du
stage embryo (E7.5) showing EpoR expression in the extraembryonic coelemic ca
of EpoR expression in the blood islands of the yolk sac. (c) E8.75 embryo displayin
yolk sac vasculature, and a lack of expression in the embryo proper (em). (d) T
ectoderm and mesoderm-derived allantois. (e) Transverse section of (b) showing E
cell component of the blood islands (red arrow). (f) Lateral view of embryo in (c) w
Late streak stage embryo (E8.0). No Epo expression could be detected either emb
stage (E8.0–8.5) embryo. (i) E9.0 embryo showed a lack of Epo expression in
detected when embryos were hybridized with sense probes in all stages studied (blood islands is closely associated with primitive hema-
topoiesis. Blood islands are formed by aggregation of
mesoderm cells: Cells at the periphery of these aggregates
differentiate into endothelial precursors, while cells inside
become primitive blood cells (Risau, 1991). Fusion of these
blood islands eventually results in the formation of a
continuous vascular channel system throughout the yolk
sac. EpoR expression can be detected in both endothelial
cells (green arrow) and primitive blood cells (red arrow, Fig.
1e). At E9.0, EpoR expression is strong in the extraem-
bryonic vessel networks (yolk sac vasculature, ysv; Fig. 1c)
as well as vitelline vessels (Fig. 1f), which develop
embryonically and are responsible for connecting the
embryonic vasculature with the yolk sac vasculature (Rugh
and Somogyi, 1968).
In contrast to high levels of EpoR expression in extra-
embryonic tissues, Epo, which encodes the only known
ligand for the EPOR, is undetectable, either extra- or intra-
embryonically during these stages of embryonic develop-
ment (Figs. 1g–i). Thus, similar to initiation of primitive
erythrocytes in the yolk sac (Lee et al., 2001; Lin et al.,
1996; Wu et al., 1995), the initiation and formation of the
extraembryonic vasculature is probably EPO-independent
(see below).ring early embryogenesis. Embryos are viewed laterally. (a) Early head-fold
vity, the chorion, and in the mesoderm derived allantois (all). (b) High level
g EpoR expression in the extraembryonic vessel network, specifically in the
ransverse section of (a) shows expression is confined to extraembryonic
poR expression in both endothelial cells (green arrow) and primitive blood
ith anterior to the left; EpoR expression is present in the vitelline vessels. (g)
ryonically or extraembryonically. (h) Lack of Epo expression in head-fold
both the extraembryonic and embryonic regions. No expression could be
data not show). Scale bar = 250 Am in a–c and g–i; 1000 Am in d–f.
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Around E8.5–9.0, the embryonic vessels connect with
the extra-embryonic vasculature through umbilical and
vitelline vessels and fetal circulation begins. The yolk-sac-
derived primitive nucleated red blood cells fill the embry-
onic vasculature. One day later, the liver rudiment is formed
and soon receives hematopoietic stem cells and progenitors
generated from the yolk sac or/and from the aorta-genital
ridge-mesonephros (AGM) region. Figs. 2a and b show the
overlapping expression of Epo and EpoR at E10.0 in the
vasculature, which leads to the hepatic primordium (hpv).
At E10.5, both Epo and EpoR are expressed in the dorsal
aorta (da, Figs. 2c,d), a site enriched in definitive
hematopoietic stem cells (Dieterlen-Lievre and Martin,
1981; Medvinsky and Dzierzak, 1996), suggesting that
EPO may play an autocrine role in the expansion of the
erythroid/megakaryocyte co-progenitors or erythroid pro-Fig. 2. Overlapping expressions of Epo and EpoR during mid-gestation stage. (a
overlapping expression of Epo and EpoR in the vasculature leading to the hepatic p
10.5 embryo sections. Transverse section at the level of the anterior part of the do
aorta (da). (e) EpoR expression in the intersomitic vessels extends rostrally. Parasa
(f) Whole mount of E10.5 embryo demonstrating positive expression of Epo in the
125 Am in d.genitor cells in these regions. The overlapping expression of
Epo and EpoR during this stage of embryonic development
fits precisely the roles of EPO and EPOR in definitive
erythropoiesis since targeted disruption of EpoR or Epo
leads to a complete block in fetal liver erythropoiesis and
causes embryonic lethality (Lin et al., 1996; Wu et al.,
1995). Whole-mount in situ hybridization analysis also
indicated that both EpoR (Fig. 2e) and Epo (Fig. 2f) are
expressed in the intersomitic vessels, with EpoR expression
extending more rostral and at higher levels as compared to
Epo expression. The fact that Epo expression is mainly
restricted to the caudal intersomitic vessels, which are less
mature than the rostral ones, suggest the possible involve-
ment of EPO signaling in initiation of angiogenesis.
Normal vasculogenesis in Epo/ and EpoR/ embryos
Functional significance of Epo and EpoR expression in
the vessels outside of the heart was ascertained by further,b) Transverse section of E10 embryos through the AGM region. Note the
rimordium (hpv). (c,d) Epo and EpoR are expressed in the dorsal aorta in E
rsal aorta reveals specific expression in cells lining the lumen of the dorsal
gittal section showing vessels in between the somites are positive for EpoR.
caudal intersomitic vessels. Scale bar = 540 Am in a and b; 250 Am in c; and
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vessel development consists of two distinct phases, vasculo-
genesis and angiogenesis. Vasculogenesis is a process in
which individual endothelial progenitors assemble vessels
de novo. This contrasts with angiogenic assembly, in which
new vessels arise from existing vessels through endothelial
branching, sprouting, migration, proliferation, and anas-
tomic interconnection with endothelial cells residing in
existing vessels (Daniel and Abrahamson, 2000). Studies
performed in quail-chick chimeras suggest that vasculo-
genesis mainly accounts for the formation of the heart,
dorsal aorta, cardinal and vitelline vessels, as well as the
extraembryonic vessels of the yolk sac (Coffin and Poole,
1988, 1991; Pardanaud et al., 1989). Angiogenesis is
thought to be responsible for the formation of vessels such
as the intersomitic arteries and the vessels in individual
organs (Coffin and Poole, 1988). As shown in Fig. 3, noFig. 3. Analysis of vasculogenesis in the knock-out embryos. (A)
Embryonic stage 9.5. The blood vessels are clearly noticeable in the
extra-embryonic yolk sac (arrows in upper panels) and dorsal aorta (arrows
in lower panels) of both WT (left panels) and mutant (right panels) embryos
at this stage. (B) PECAM-1 staining of embryo sections (upper) and yolk
sacs. Arrows indicate dorsal aorta; notice the diameter of lumen in the
mutant is comparable to WT (upper panel). Yolk sac whole mounts show
comparable PECAM-1 staining in WT and mutant at this stage (lower
panel). Scale bar = 600 Am in A and 250 Am in B.significant differences in vascular patterning were detected
in the null embryos, E9.5 or younger, as compared to the
WT or heterozygous littermates. Both intra- (lower panels,
arrows point to dorsal aorta) and extra-embryonic vascula-
tures (upper panels) are well developed in the mutant
embryos (Fig. 3A). PECAM-1 staining, a specific marker
for vascular endothelial cells, on the mutant yolk sac whole
mounts and embryonic sections further revealed that the
extraembyonic vessel network and the diameter of the
mutant dorsal aorta and the intensities of PECAM-1 staining
are comparable to that of the WT littermates (Fig. 3B).
Because earlier endothelial cell differentiation and forma-
tion of blood islands, dorsal aorta, heart, and primordial
vasculature are normal in Epo/ and EpoR/ embryos
and yolk sacs, our results suggest that earlier vasculogenesis
is EPO and EPOR independent, which is consistent with our
expression studies (Figs. 1 and 2).
Angiogenesis defects in Epo/ and EpoR/ embryos
Starting from E10.5, 1.5 days after the commencement
of blood circulation, which connects the extra-embryonic
compartment with the embryo proper, both Epo/ and
EpoR/ embryos appeared pale due to the absence of
definitive erythropoiesis (Lee et al., 2001; Wu et al.,
1995). Interestingly, both mutant embryos also showed
defects in the second wave of blood vessel formation,
especially in the head region where active angiogenesis
takes place. To confirm that this observation is not simply
due to the lack of red blood cells in the vessels, we
performed whole-mount PECAM-1 staining. The WT head
contains well-branched blood vessel networks, whereas the
complexity of cranial vasculatures in Epo/ and EpoR/
embryos was decreased: with narrower vessel diameter and
fewer branches (Fig. 4, upper panels). PECAM-1 staining
is also weaker in both mutant intersomitic vessels (Fig. 4,
middle panels), where high levels of Epo and EpoR
expression are detected in the WT embryos by in situ
hybridization analysis (Figs. 2e,f). This angiogenesis defect
happens 2 days before the onset of observable cardiac
defects (Wu et al., 1999) and is therefore likely to be a
primary defect in angiogenesis.
At E12.5, angiogenesis defects became even more
severe. We performed PECAM-1 staining on embryonic
sections across the neural tube areas since (1) angiogenesis
is very active during this stage of embryogenesis; and (2)
high levels of both Epo and EpoR expressions can be
detected in the neural tube region (Yu et al., 2002 and our
unpublished observation). Lower panels in Fig. 4 clearly
demonstrated angiogenesis defects in the neural tube
regions: capillary sprouting is severely diminished in both
mutants, as compared to the WT control where angiogenic
sprouting is numerous in the neural tube and surrounding
mesenchyme tissues. Taken together, these results suggest
that EPO and EPOR are vital factors for angiogenesis but
dispensable for vasculogenesis.
Fig. 4. Analysis of angiogenesis defects in the mutant embryos. Upper and
middle panels, embryonic stage 10.5. Notice clear defects of vascular
network in the head region (upper panels) or intersomitic region (middle
panels) of both mutant embryos based on whole mounts for PECAM
staining. Lower panels, embryonic stage 12.5. PECAM-stained sections
show lack of extensive vascular network in neural tube regions in both
types of mutant animals. Capillary sprouting is severely diminished in the
neural tube in the mutant embryos, as compared to the WT control where
angiogenic sprouting is numerous (arrowheads).
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and partial rescue of the angiogenic defects in Epo/
embryos
If the above defects were a direct result of lacking EPO
or EPOR signaling, we would expect to rescue the
vascular defects of Epo/ embryos with an Epo trans-
gene. For this, we generated transgenic lines carrying
human Epo cDNA (see Materials and methods), using
bMHC promoter (Rindt et al., 1993). Because EPO is a
secreted hormone, its effects will be seen systemically. Five
founders survived to adulthood but three died 4–7 weeks
after birth due to, at least in part, spleenomegaly and
extremely high hematocrit (data not shown). Two surviving
lines, with hematocrit ranging 60–75%, were used for
further studies.
Based on RT-PCR analysis, hEpo transgene expression
can be detected as early as E11 (Tran and Sucov,
unpublished observation). As a result of overexpression
of hEpo, a significant increase in the number of vessels,
as visualized by FITC-labeled lectin (Fig. 5A, upperright), was observed in adult mice of two independent
transgenic lines. We also detected significant morpholog-
ical changes in the vessel structures. Instead of straight
small vessels branching out from the large vessels, the
transgenic mice contained abundant tortuous vessels (Fig.
5A, lower right). When crossed to EPO-deficient mice,
we found that the vascular defects in the null embryos
were partially rescued by the hEpo transgene expression
(Fig. 5B).
EPO and the expression of angiogenic factors
Vascular endothelial growth factor (VEGF) and angio-
poietin-1 (Ang-1) are two important factors involved in the
vascular formation during embryogenesis. VEGF is crucial
for de novo vasculogenesis, the first wave of vasculo-
genesis, as well as for angiogenesis. Ang-1, on the other
hand, has less effect on vasculogenesis but is indispensable
for angiogenesis. To investigate the possible mechanism
involved in EPO-controlled angiogenesis, we first compared
the expression levels of Vegf and Ang-1 in E12.5 EpoR+/+
and EpoR/ embryonic head region by Northern blot
analysis. Interestingly, the expression of Vegf is up-regulated
by at least 4-fold in the receptor null embryos (Fig. 6A, left
panel), which is most likely due to the hypoxic condition
caused by erythropoietic defects (Wu et al., 1995), since
Vegf expression levels are comparable in the placenta tissue
of WT and mutant embryos (Fig. 6A, right panel), a tissue
that is not hypoxic due to maternal blood circulation.
However, the expression of Ang-1 is reduced by 2-fold, as
compared with WT controls (Fig. 6A, left panel), suggesting
that the EPO/EPOR signaling pathway may somehow
modulate Ang-1 expression.
To prove that the decrease in Ang-1 levels is a direct
result of the lack of EPO signaling, we employed HUVEC
cells as well as primary murine aortic-derived endothelial
cells (data not shown), which express the endogenous EpoR
and can respond to EPO stimulation (Anagnostou et al.,
1990, 1994; Carlini et al., 1995). Consistent with our in vivo
studies, EPO stimulation under normoxic conditions
resulted in a 2- to 4-fold increase in Ang-1 expression in
HUVEC cells by Northern blot analysis (Fig. 6B, left), or
2.5-fold based on Q-PCR (Fig. 6B, right). Interestingly,
under the normoxic condition, Vegf levels are also induced
upon EPO stimulation (Fig. 6B). This provides the first
evidence that EPO/EPOR signaling pathway controls the
expressions of Ang-1 and Vegf, two crucial angiogenic
factors, and suggests that decreased Ang-1 expression may
directly or indirectly contribute to the angiogenesis defects
seen in the mutant embryos.Discussion
In this study, we addressed the potential roles of EPO and
EPOR in angiogenesis. Our in situ hybridization analysis
Fig. 5. Overexpression of hEpo induces adult angiogenesis and significantly rescues the vascular defects seen in Epo null embryos. (A) FITC-Lectin staining of
the WT (left panels) and Epo transgenic (right panels) mice. Notice many more small tortuous vessels in the transgenic animal. Lower panels show the tortuous
vessels in the transgenic ear. Scale bar = 800 Am in upper panels and 200 Am in lower panels. (B) Vascular network of the WT vs. Epo/; EpoTg embryo:
PECAM staining, showing partial rescue of Epo/ embryo with significantly improved vessel structure and network (right) compared to Epo null embryo
(middle).
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situ in the vasculature. By analyzing Epo/ and EpoR/
mice as well as mice overexpressing Epo, we also provided
the first genetic evidence for the roles of EPO and EPOR in
angiogenesis.
EPO and EPOR are crucial for angiogenesis
The formation of new blood vessels (angiogenesis) is
essential for embryonic development and contributes to
the pathogenesis of numerous disorders. In contrast,
insufficient angiogenesis may lead to tissue ischemia
and failure. The effect of EPO on in vivo vasculogenesis
has not been previously elucidated. However, the potential
roles of EPO and EPOR in vascular function have been
indicated in both in vitro and semi-in vivo studies: rEPO
has been shown to increase microvascular branch for-
mation from rat aortic rings in a standard angiogenic
assay. In addition, rEPO has been shown to up-regulate
expression of several genes involved in vascular function,
signal transduction, and energy transfer, in culturedendothelial cells (Banerjee et al., 2000; Carlini et al.,
1995; Fodinger et al., 2000; Heidenreich et al., 1991;
Wang and Vaziri, 1999). Recent studies also link EPO
with malignant tumor growth (Yasuda et al., 2003), at
least in part, due to its angiogenic effects (Ribatti et al.,
2003). Our study demonstrates that EPO and EPOR
regulate angiogenesis in vivo, a process involving the
formation of new vessels on existing vessels, but not de
novo vasculogenesis. Interestingly, vasculatures in both
Epo/ and EpoR/ embryos are equally affected,
suggesting EPOR is the signaling receptor for EPO in
regulating angiogenesis.
The defects seen in the mutant vasculatures fit precisely
with the patterns of Epo and EpoR expressions: EpoR is
expressed in the yolk sac blood islands and vascular
structures. However, Epo is absent during this early stage
of embryogenesis, the period that vasculogenesis takes
place. Thus, similar to initiation of primitive erythropoiesis
in the yolk sac blood islands (Lee et al., 2001; Wu et al.,
1995), the initiation of vascular structures is also EPO-
independent. It is only by E9.0–E10.5 when EPO starts to
Fig. 6. EPO regulates Ang-1 and Vegf expression. (A) Northern blot analysis of Ang-1 and Vegf expressions in E12.5 EpoR null (lane 2) and WT embryo (lane
1) heads (left) and placenta (right). Vegf expression is significantly increased by 4-fold in the mutant embryos as compared to the WT (upper panel). The same
blot was reprobed with Ang-1 probe (middle). Ang-1 expression is significantly lower (about 2 fold) in the null embryo compared to the WT. Vegf expression,
on the other hand, is not changed in the placental tissues: 15 and 25 Ag of total RNAwere loaded, respectively. Actin is used as loading control. (B) The levels
of Ang-1 and Vegf were determined by Northern blot analysis (left) or real-time quantitative PCR (right). EPO (10 U) stimulation leads to increased Vegf and
Ang-1 expression at 2 and 5 h.
N. Kertesz et al. / Developmental Biology 276 (2004) 101–110108be produced intraembryonically that angiogenesis defects
become apparent.
Recently, Suzuki et al. (2002) showed rescue of lethality
of EpoR null mutant mice upon expression of EpoR under
an erythroid specific promoter GATA-1 and concluded that
nonhematopoietic expression of EpoR is dispensable to
normal mouse development. This discrepancy could be due
to the (1) different EpoR-deficient animals were used. The
EpoR knockout mice Suzuki et al. used carries an exon-3-
specific deletion (Kieran et al., 1996) that leads to erythroid
defects less severe than our mutant line in which the
promoter and exons 1–6 are completely deleted (Wu et al.,
1995). Importantly, the erythroid colony formation defects
of our EpoR/ progenitors cannot be rescued by TPO (Wu,
unpublished observation), different from what was reported
(Kieran et al., 1996). (2) The angiogenesis defects seen in
Epo- and EpoR-deficient embryos may happen transiently
during a specific stage of embryonic development, similar to
the erythroid defects seen in RXRa/ embryos at E10.25–
11.25 (Makita et al., 2001) or Stat5a/5b/ mice during
fetal stage (Socolovsky et al., 1999). (3) Because GATA-1 is
expressed in the Flk1+ extra-embryonic mesoderm, as well
as the hematopoietic cells (Fujimoto et al., 2001), the EpoR
transgene, under the control of the GATA-1 promoter, may
be expressed at low levels in the hemangioblasts or vessel
endothelium, and although difficult to be detected, sufficient
to rescue the vessel defects. Further investigation will help
in distinguishing these possibilities.Angiogenic defects and hypoxia
The lack of EPO or EPOR is clearly accompanied by
alterations in the relative oxygen tensions in the mutant
animals. However, the angiogenesis defects described in this
study are unlikely due to general hypoxia. Hypoxia will
induce the expression and activation of transcription factor
HIF-1a, which in turn activates gene expression, such as
Vegf and promotes vessel formation. Therefore, hypoxia
conditions usually cause increased angiogenesis, rather than
decreased angiogenesis, as we observed in this study.
Furthermore, the onset and location of angiogenesis defects
correlate well with endogenous Epo expression and EPO
production, suggesting that EPO/EPOR plays an active role
in promoting new vessel formation.
During vertebrate embryogenesis, blood cell formation
and vasculogenesis are intertwined temporally and spatially
to satisfy the metabolic requirements of the developing
embryo. It is interesting that EpoR is expressed early in the
murine yolk sac where the blood cell and vessel formation
takes place, and EPO and EPOR are required for the second,
definitive waves of erythropoiesis (Lee et al., 2001) as well
as the second wave of vasculogenesis, as indicated in this
study. Whether the low shear stress, i.e., decreased
hematocrit due to anemia, in the vasculature of the mutant
embryo could contribute to the angiogenesis defects
observed in this study needs to be further investigated.
However, studies on zebrafish mutants affecting either the
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esis (Paw and Zon, 2000; Weinstein et al., 1996) seem to
suggest that the formation of the zebrafish circulation
system are not severely influenced by the low shear stress
caused by hematopoietic defects.
EPO and Vegf/Ang-1 expressions
Although the precise mechanism by which EPO regu-
lates angiogenesis remains to be studied, it is most likely
initiated by binding of EPO to EPOR on endothelial cells
and activation of the downstream signaling cascades, since
both Epo- and EpoR-deficient mice demonstrated identical
phenotypes throughout our studies.
We have shown decreased Ang-1 expression in the
mutant embryos. Conversely, EPO stimulation leads to
increased Ang-1 levels, indicating that EPO may regulate
angiogenesis through, at least in part, by modulating Ang-1
expression. The mechanism whereby EPO affects Ang-1
expression remains to be further elucidated. Recent studies
have demonstrated that Ang-1 induces endothelial cell
sprouting, endothelial cell migration, and tubule-like struc-
ture formation in vitro (Fujikawa et al., 1999; Hayes et al.,
1999; Koblizek et al., 1998). In addition, increased
branching and vessel density is observed in vivo upon
overexpression of Ang-1, providing strong evidence of an
active role for Ang-1 in both embryonic and adult angio-
genesis (Suri et al., 1998). Interestingly, increased vessel
density is also evident in hEpo transgenic animals.
Ang-1 regulates endothelial cells by binding to its
cognate receptor, Tie2 (Yancopoulos et al., 2000). Recent
studies suggest that EPO and Ang-1 may employ similar
signaling pathways for their biological functions; for
example, STAT3 and STAT5 were found to be potential
targets of Tie2 activation. As STAT3 and/or STAT5 have
been implicated in the regulation of EPO-mediated bio-
logical effects (for a review, see (Akira, 1999), some of
the Tie2 functions in endothelial cells may be regulated
by the cross-talk from the EPOR signaling pathway. Both
Epo and Vegf are under the control of HIF-1a, a
transcription factor whose activity is up-regulated under
hypoxic conditions. It is interesting to observe up-
regulation of Vegf expression upon EPO stimulation under
normoxic conditions. The precise mechanism and bio-
logical significance of such regulation needs further
investigation.
Multifunction of EPO and EPOR: a mode of action
Generation of animals lacking either Epo or EpoR genes
established genetic systems to address the function of this
ligand/receptor pair in erythropoiesis (Wu et al., 1995), in
cardiac morphogenesis (Wu et al., 1999), in neurogenesis
(Yu et al., 2002), and in angiogenesis (this study). The
mutant phenotypes observed in the mutant mice fit precisely
the temporal and spatial expression patterns of Epo andEpoR genes. First, EpoR is always expressed before that of
Epo during embryonic development to bprimeQ or prepare
cells to respond to EPO stimulation. Secondly, Epo and
EpoR expression are spatially separated in the yolk sac:
EpoR is expressed in the yolk sac blood island and
vasculatures, but Epo expression is absent in the yolk sac.
This spatially uncoupled expression pattern provides a
cellular mechanism as to why the initiation of primitive
erythropoiesis and primitive vasculogenesis in the yolk sac
are independent of EPO and EPOR even though the cells are
fully competent to respond to EPO stimulation. Only until
later when both Epo and EpoR are co-expressed intra-
embryonically can defects in definitive erythropoiesis in the
fetal liver, hypoplasia in the myocardium, and defects in
angiogenesis be observed.Acknowledgments
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